Clinical Trials Logo

Patient Preference clinical trials

View clinical trials related to Patient Preference.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05910164 Active, not recruiting - Clinical trials for Patient Satisfaction

Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim

PELGRAZ
Start date: June 9, 2023
Phase:
Study type: Observational

Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the lack of hospitalization resources. The prevention of NF is well documented and its success depends on the risks of developing NF related to the type of chemotherapy protocol used and the profile of the patient and his disease. Pegfilgrastim (G-CSF, biosimilar medicine) injection has been shown to prevent (febrile) neutropenia. It is routinely prescribed on an outpatient basis for patients treated with chemotherapy (CT), several thousand times a year in our geographical area. In order to take into account patient preferences and help clinical decision-making, this study will be conducted on the basis of self-administered questionnaires. The aim of the research is to assess patient preference for receiving administration of PELGRAZ (Accord Healthcare) using a prefilled syringe or a prefilled pen device. In a second step, this study will evaluate the learning of the patient and his autonomy during a pen self-injection guided by a nurse.

NCT ID: NCT05284591 Active, not recruiting - Multiple Myeloma Clinical Trials

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

MYLENE
Start date: July 6, 2022
Phase:
Study type: Observational

MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany. Patients observed in this study will be transplant ineligible NDMM patients for which the physician foresees an anti-myeloma therapy using DRd regimen as per local label. 250 NDMM patients treated with DRd will be enrolled (excluding screening failures, i.e., enrolled patients not fulfilling selection criteria identified before treatment start will be replaced) within 12 months in a proportion of approximately 1/3 patients receiving daratumumab sc and 2/3 patients receiving daratumumab iv as per physician's decision.

NCT ID: NCT03118323 Active, not recruiting - Patient Preference Clinical Trials

Patients' Willingness-to-pay of Endodontic Treatment

Start date: July 8, 2017
Phase:
Study type: Observational

The aim of the present study is to determine the monetary value of endodontic treatment (primary root canal treatment) compared to the alternative treatment options, such as extraction with or without subsequent insertion of a dental implant or placement of a fixed dental prosthesis.

NCT ID: NCT02975635 Active, not recruiting - Patient Preference Clinical Trials

Patients' Preferences for Repair Versus Replacement Restorations

Start date: March 15, 2017
Phase:
Study type: Observational

Partially defective dental restorations might either be treated by complete replacement or by repair of the affected region. Repair restorations are a scientifically proven approach to manage failed restorations, but probably unknown to most patients. Results from this study and findings on the predictors of patients' therapy decisions might improve future patient information documents.